Armata Pharmaceuticals
ARMP
23 hedge funds and large institutions have $3.86M invested in Armata Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 1 closing their positions.
0.04% less ownership
Funds ownership: 3.93% → 3.88% (-0.04%)
4% less funds holding
Funds holding: 24 → 23 (-1)
35% less capital invested
Capital invested by funds: $5.93M → $3.86M (-$2.07M)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $156K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$133K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$18.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.61K |
| 4 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$6.21K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$428 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$67.9K |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$58.5K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$57.1K |
| 4 |
Renaissance Technologies
New York
|
-$9.13K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$7.44K |
ARMP Hedge Fund Activity: Q2 2024 in Review
23 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2024, worth a combined $3.86M — down 35% from $5.93M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ARMP and 0 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 6 added.
The largest buyer was Vanguard Group, adding an estimated $133K. The largest seller was Susquehanna International Group, cutting an estimated $67.9K.
- 23 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2024, down from 24 in Q1 2024.
- Funds reported $3.86M of Armata Pharmaceuticals stock for Q2 2024, down 35% quarter-over-quarter.
- 0 funds opened new Armata Pharmaceuticals positions in Q2 2024 and 1 closed out, a net change of -1 holder.
- The largest Armata Pharmaceuticals buyer in Q2 2024 was Vanguard Group, an estimated $133K added.
- The largest Armata Pharmaceuticals seller in Q2 2024 was Susquehanna International Group, an estimated $67.9K sold.
Based on aggregated 13F filings for Q2 2024.